PMID- 15196531
OWN - NLM
STAT- MEDLINE
DCOM- 20040824
LR  - 20141120
IS  - 0959-8049 (Print)
IS  - 0959-8049 (Linking)
VI  - 40
IP  - 10
DP  - 2004 Jul
TI  - Expression of HER2 and its association with AP-2 in breast cancer.
PG  - 1485-95
AB  - The aim of the study was to investigate the relationship between the expression 
      of human epidermal growth factor receptor 2 (HER2) and activator protein 2 
      (AP-2), as well as the prognostic significance of HER2 in breast cancer. HER2 and 
      AP-2 expressions were immunohistochemically (IHC) analysed in a large 
      prospective, consecutive series of 425 breast cancer patients diagnosed and 
      treated between 1990 and 1995 at the Kuopio University Hospital, Kuopio, Finland. 
      In a subset of patients (n = 71), the gene amplification status was examined by 
      using a chromogenic in situ hybridisation (CISH) analysis. Expression of HER2 was 
      studied in relation to AP-2, clinicopathological parameters and patients' 
      survival. Pathological membranous overexpression of the HER2 receptor was seen in 
      13% of the carcinomas, which was related both to gene amplification (78% of the 
      cases) and high nuclear expression of AP-2 (67%, P = 0.007). HER2-positivity was 
      most often seen in carcinomas having both high nuclear and high cytoplasmic AP-2 
      expression (P < 0.001). In the univariate survival analyses HER2-positivity 
      predicted a shorter recurrence-free survival (RFS) (P < 0.0001) and a shorter 
      breast cancer-related survival (BCRS) (P = 0.0063) in the whole patient group, as 
      well as in the subgroup of node-negative patients. In the node-positive patients, 
      HER2-positivity predicted only a shorter RFS. Combined expression of HER2 and 
      nuclear AP-2 resulted in the separation of four groups with different prognoses, 
      the best prognosis being for patients in the HER2-/AP-2+ group and the worse 
      prognosis for those in the HER2+/AP-2- group. In the multivariate survival 
      analyses, HER2-positivity independently predicted a shorter RFS in the whole 
      patient group (P = 0.0067), as well as in the subgroup of node-positive patients 
      (P = 0.0209). In conclusion, pathological membranous overexpression of the HER2 
      receptor in breast cancer is related both to gene amplification and a high AP-2 
      expression. Combining HER2 and AP-2 expressions may provide valuable information 
      on the prognosis of breast cancer patients.
FAU - Pellikainen, J
AU  - Pellikainen J
AD  - Department of Pathology, Kuopio University Hospital, Kuopio, Finland.
FAU - Naukkarinen, A
AU  - Naukkarinen A
FAU - Ropponen, K
AU  - Ropponen K
FAU - Rummukainen, J
AU  - Rummukainen J
FAU - Kataja, V
AU  - Kataja V
FAU - Kellokoski, J
AU  - Kellokoski J
FAU - Eskelinen, M
AU  - Eskelinen M
FAU - Kosma, V-M
AU  - Kosma VM
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Eur J Cancer
JT  - European journal of cancer (Oxford, England : 1990)
JID - 9005373
RN  - 0 (DNA-Binding Proteins)
RN  - 0 (Ki-67 Antigen)
RN  - 0 (Neoplasm Proteins)
RN  - 0 (Transcription Factor AP-2)
RN  - 0 (Transcription Factors)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Analysis of Variance
MH  - Breast Neoplasms/*metabolism
MH  - Cell Division
MH  - DNA-Binding Proteins/*metabolism
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Immunohistochemistry/methods
MH  - Ki-67 Antigen/metabolism
MH  - Middle Aged
MH  - Neoplasm Proteins/*metabolism
MH  - Prognosis
MH  - Prospective Studies
MH  - Receptor, ErbB-2/*metabolism
MH  - Survival Analysis
MH  - Transcription Factor AP-2
MH  - Transcription Factors/*metabolism
EDAT- 2004/06/16 05:00
MHDA- 2004/08/25 05:00
CRDT- 2004/06/16 05:00
PHST- 2003/11/12 00:00 [received]
PHST- 2004/02/13 00:00 [revised]
PHST- 2004/02/25 00:00 [accepted]
PHST- 2004/06/16 05:00 [pubmed]
PHST- 2004/08/25 05:00 [medline]
PHST- 2004/06/16 05:00 [entrez]
AID - S095980490400214X [pii]
AID - 10.1016/j.ejca.2004.02.020 [doi]
PST - ppublish
SO  - Eur J Cancer. 2004 Jul;40(10):1485-95. doi: 10.1016/j.ejca.2004.02.020.